Protalix (PLX) Shares Hit as FDA Extends Taliglucerase Alfa PDUFA by Three Months

Protalix BioTherapeutics, Inc. (AMEX: PLX), got slammed early, down as much as 2 percent to $4.85, following reports the U.S. FDA moved the Prescription Drug User Fee Act (PDUFA) goal date of the New Drug Application (NDA) for taliglucerase alfa to May 1, 2012, a three-month extension from the previous PDUFA date of February 1, 2012.

Shares have moved higher since the initial investor reaction, now 15.5 percent lower on the session.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Gossamer Bio raises up to $250M in private placement for PAH drug
• Keenova doses first patient in Phase 3 hammer toe drug trial